Springe zum Inhalt
| Eingeschlossene Patienten: 18.941(Stand 04. November 2019) | |
| Amgevita® (Adalimumab) | 44 |
| Benepali® (Etanercept) | 628 |
| Cimzia® (Certolizumab) | 898 |
| Enbrel® (Etanercept) | 2857 |
| Erelzi® (Etanercept) | 201 |
| Flixabi® (Infliximab) | 2 |
| Hulio® (Adalimumab) | 5 |
| Humira® (Adalimumab) | 2904 |
| Hyrimoz® (Adalimumab) | 45 |
| Imraldi® (Adalimumab) | 49 |
| Inflectra™ (Infliximab) | 16 |
| Kevzara® (Sarilumab) | 104 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1459 |
| Olumiant® (Baricitinib) | 326 |
| Orencia® (Abatacept) | 788 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 10 |
| Rixathon® (Rituximab) | 9 |
| RoActemra® (Tocilizumab) | 1318 |
| Simponi® (Golimumab) | 441 |
| Xeljanz® (Tofacitinib) | 250 |
| Zessly® (Infliximab) | 2 |
| Kontrollen | 5734 |
Nach oben scrollen
